{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:54:49Z","timestamp":1773867289826,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T00:00:00Z","timestamp":1541203200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12902-018-0303-x","type":"journal-article","created":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T09:44:21Z","timestamp":1541238261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor"],"prefix":"10.1186","volume":"18","author":[{"given":"Miguel \u00c1ngel","family":"G\u00f3mez-S\u00e1mano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Enrique","family":"Baquerizo-Burgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa Fabiola Coronel","family":"Coronel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buileng Daniela","family":"Wong-Campoverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Villanueva-Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Molina-Botello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Alonso","family":"Avila-Rojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Palacios-B\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Cuevas-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Gomez-Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Zentella-Dehesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Aguayo-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Gulias-Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,3]]},"reference":[{"key":"303_CR1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2017","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels: International Diabetes Federation; 2017. \n                    http:\/\/www.diabetesatlas.org","edition":"8"},{"key":"303_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/1078155210378913","volume":"17","author":"NM Agostino","year":"2011","unstructured":"Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract. 2011;17:197\u2013202. \n                    https:\/\/doi.org\/10.1177\/1078155210378913\n                    \n                  .","journal-title":"J Oncol Pharm Pract"},{"key":"303_CR3","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1200\/JCO.2004.04.217","volume":"22","author":"M Breccia","year":"2004","unstructured":"Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol. 2004;22:4653\u20135. \n                    https:\/\/doi.org\/10.1200\/JCO.2004.04.217\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"303_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1042\/CS20090348","volume":"118","author":"D Mokhtari","year":"2010","unstructured":"Mokhtari D, Welsh N. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond). 2010;118:241\u20137.","journal-title":"Clin Sci (Lond)"},{"key":"303_CR5","first-page":"1","volume":"9","author":"J Lau","year":"2014","unstructured":"Lau J, Zhou Q, Sutton SE, Herman AE, Schmedt C, Glynne R. Inhibition of c-kit is not required for reversal of hyperglycemia by imatinib in NOD mice. PLoS One. 2014;9:1\u20135.","journal-title":"PLoS One"},{"key":"303_CR6","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1038\/sj.onc.1204704","volume":"20","author":"DA Tuveson","year":"2001","unstructured":"Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054\u20138. \n                    https:\/\/doi.org\/10.1038\/sj.onc.1204704\n                    \n                  .","journal-title":"Oncogene"},{"key":"303_CR7","doi-asserted-by":"publisher","first-page":"18895","DOI":"10.1073\/pnas.0810246105","volume":"105","author":"C Louvet","year":"2008","unstructured":"Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008;105:18895\u2013900. \n                    https:\/\/doi.org\/10.1073\/pnas.0810246105\n                    \n                  .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"303_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1096\/fj.06-6910com","volume":"21","author":"R H\u00e4gerkvist","year":"2007","unstructured":"H\u00e4gerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J. 2007;21:618\u201328. \n                    https:\/\/doi.org\/10.1096\/fj.06-6910com\n                    \n                  .","journal-title":"FASEB J"},{"key":"303_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4158\/EP.13.2.126","volume":"13","author":"D Dingli","year":"2007","unstructured":"Dingli D, Wolf RC, Vella A. Imatinib and type 2 diabetes. Endocr Pract. 2007;13:126\u201330.","journal-title":"Endocr Pract"},{"key":"303_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1756-8722-2-30","volume":"2","author":"JP Lee","year":"2009","unstructured":"Lee JP, Birnstein E, Masiello D, Yang D, Yang AS. Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study. J Hematol Oncol. 2009;2:30.","journal-title":"J Hematol Oncol"},{"key":"303_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/jcb.24402","volume":"114","author":"MSH Akash","year":"2013","unstructured":"Akash MSH, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2013;114:525\u201331.","journal-title":"J Cell Biochem"},{"key":"303_CR12","first-page":"1","volume":"9","author":"CQ Xia","year":"2014","unstructured":"Xia CQ, Zhang P, Li S, Yuan L, Xia T, Xie C, et al. C-Abl inhibitor imatinib enhances insulin production by \u03b2 cells: C-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2. PLoS One. 2014;9:1\u201311.","journal-title":"PLoS One"},{"key":"303_CR13","doi-asserted-by":"publisher","first-page":"13622","DOI":"10.1073\/pnas.0501758102","volume":"102","author":"AM Wolf","year":"2005","unstructured":"Wolf AM, Wolf D, Rumpold H, Ludwiczek S, Enrich B, Gastl G, et al. The kinase inhibitor imatinib mesylate inhibits TNF-\u03b1 production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A. 2005;102:13622\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"303_CR14","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cellbi.2006.08.006","volume":"30","author":"R H\u00e4gerkvist","year":"2006","unstructured":"H\u00e4gerkvist R, Makeeva N, Elliman S, Welsh N. Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro. Cell Biol Int. 2006;30:1013\u20137. \n                    https:\/\/doi.org\/10.1016\/j.cellbi.2006.08.006\n                    \n                  .","journal-title":"Cell Biol Int"},{"key":"303_CR15","doi-asserted-by":"publisher","first-page":"33623","DOI":"10.1074\/jbc.M109.085084","volume":"285","author":"N Wijesekara","year":"2010","unstructured":"Wijesekara N, Krishnamurthy M, Bhattacharjee A, Suhail A, Sweeney G, Wheeler MB. Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem. 2010;285:33623\u201331. \n                    https:\/\/doi.org\/10.1074\/jbc.M109.085084\n                    \n                  .","journal-title":"J Biol Chem"},{"key":"303_CR16","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1210\/jc.2010-0086","volume":"95","author":"S Fitter","year":"2010","unstructured":"Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino ACW. Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab. 2010;95:3763\u20137. \n                    https:\/\/doi.org\/10.1210\/jc.2010-0086\n                    \n                  .","journal-title":"J Clin Endocrinol Metab"},{"key":"303_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1042\/CS20130560","volume":"128","author":"RG Fred","year":"2015","unstructured":"Fred RG, Boddeti SK, Lundberg M, Welsh N. Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells. Clin Sci (Lond). 2015;128:17\u201328. \n                    https:\/\/doi.org\/10.1042\/CS20130560\n                    \n                  .","journal-title":"Clin Sci (Lond)"},{"key":"303_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00125-013-2868-2","volume":"56","author":"D Mokhtari","year":"2013","unstructured":"Mokhtari D, Al-Amin A, Turpaev K, Li T, Idevall-Hagren O, Li J, et al. Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5\u2032-phosphatase interaction with c-Abl. Diabetologia. 2013;56:1327\u201338.","journal-title":"Diabetologia"},{"key":"303_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.tem.2015.09.003","volume":"26","author":"A Fountas","year":"2015","unstructured":"Fountas A, Diamantopoulos LN, Tsatsoulis A. Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? Trends Endocrinol Metab. 2015;26:643\u201356. \n                    https:\/\/doi.org\/10.1016\/j.tem.2015.09.003\n                    \n                  .","journal-title":"Trends Endocrinol Metab"},{"key":"303_CR20","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.2337\/db08-0506.P.O.P","volume":"58","author":"PO Prada","year":"2009","unstructured":"Prada PO, Ropelle ER, Moura RH, de Souza CT, Pauli JR, Rocco SA, et al. EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice. Diabetes. 2009;58:2910\u20139. \n                    https:\/\/doi.org\/10.2337\/db08-0506.P.O.P\n                    \n                  .","journal-title":"Diabetes"},{"key":"303_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2337\/db08-0080","volume":"58","author":"MS Han","year":"2009","unstructured":"Han MS, Chung KW, Cheon HG, Rhee SD, Yoon C-H, Lee M-K, et al. Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db\/db mice. Diabetes. 2009;58:329\u201336. \n                    https:\/\/doi.org\/10.2337\/db08-0080\n                    \n                  .","journal-title":"Diabetes"},{"key":"303_CR22","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00277-012-1493-3","volume":"91","author":"A Salaroli","year":"2012","unstructured":"Salaroli A, Loglisci G, Serrao A, Alimena G, Breccia M. Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFR\u03b2 rearrangement and type 1 diabetes. Ann Hematol. 2012;91:1823\u20134.","journal-title":"Ann Hematol"},{"key":"303_CR23","doi-asserted-by":"publisher","first-page":"33944","DOI":"10.18632\/oncotarget.5580","volume":"6","author":"A Iurlo","year":"2015","unstructured":"Iurlo A, Orsi E, Cattaneo D, Resi V, Orofino N, Scium\u00e8 M, et al. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients\u00a0: a real clinical problem\u00a0? Oncotarget. 2015;6:33944\u201351.","journal-title":"Oncotarget"},{"key":"303_CR24","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.leukres.2008.01.015","volume":"32","author":"M Breccia","year":"2008","unstructured":"Breccia M, Muscaritoli M, Cannella L, Stefanizzi C, Frustaci A, Alimena G. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res. 2008;32:1626\u20138.","journal-title":"Leuk Res"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-018-0303-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12902-018-0303-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-018-0303-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T20:07:41Z","timestamp":1572725261000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-018-0303-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1186\/s12902-018-0303-x","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,3]]},"assertion":[{"value":"25 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was submitted and approved by the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Comite de Etica en Investigacion\/Comite de investigacion on 11th of July 2016. REF 1974. The ethics committee waivered the need for consent from each patient since we do not include personal information.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"77"}}